Introduction: Elderly patients (aged≥ 75 years), with newly diagnosed acute myeloid
leukemia (ND AML) frequently are ineligible to receive intensive chemotherapy (IC) and …

Abstract Treatment options for patients with acute myeloid leukemia (AML), who are unfit for
induction chemotherapy are unsatisfactory. Overall survival (OS) superiority has not been …

Acute myeloid leukemia (AML) is a disease of older adults [1] and has a median age of 68
years at the time of diagnosis. The management of AML in older patients (> 60 years) is far …

Prognosis for older patients with acute myeloid leukemia (AML) is generally inferior to that in
younger patients. However, there is no consensus definition of" older adult" regarding …

Despite significant advances in the treatment of acute myeloid leukemia (AML), outcomes in
older patients continue to be suboptimal, due to a combination of adverse disease …

Introduction Initial treatment selection for older adults with AML remains challenging.
Historically, clinicians and patients had to choose between intensive chemotherapy (7+ 3) …

Advances in the treatment of elderly and frail patients with... : Current Opinion in Oncology
Advances in the treatment of elderly and frail patients with acute myeloid leukemia : Current …

Acute myeloid leukemia (AML) is the second most common leukemia among adults.
Although the median age at diagnosis is 67 years, with approximately one third of patients …

The United States Food and Drug Administration has approved several oral, targeted
therapies for the treatment of Acute Myeloid Leukemia (AML) in recent years. These agents …

Acute myeloid leukemia has a poor prognosis in older adults, and its management is often
unclear due to its underrepresentation in clinical trials. Both overall survival (OS) and health …